A french vaccine producer, Valneva SE has recently announced that it has successfully been approved by the US Food and Drug Administration (FDA) to commence its Phase II Clinical Trials and licensure of its single shot Chikungunya vaccine, VLA1553.
Chikungunya is a mosquito-borne viral disease that was caused by the Togaviridae virus transmitted from Aedes mosquitoes, according to the World Health Organization.
This vaccine is a single dose, a live-attenuated candidate that is to provide immunization against the Chikungunya virus. It was granted Fast Track designation by the US FDA back in 2018.
Valvena SE said on 25th March that its Phase III pivotal trial will be subjected to a detailed protocol review, double-blinded, placebo-controlled, and multi-center study in almost 4,000 healthy adults.
Chief Medical Officer of Valvena, Wolfgang Bender says that they are excited to potentially have the vaccine available by the end of 2022, against the virus that threatens public health.